ROIV FDA approval for oral LISRAYA dermatomyositis therapy
ROIV said the FDA approved LISRAYA as the first oral-targeted therapy for dermatomyositis, launching immediately.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ROIV FDA approval of LISRAYA for dermatomyositis; launches immediately
ROIV says the FDA approved LISRAYA as the first oral targeted therapy for dermatomyositis, with launch immediately.
FDA approval for ROIV’s LISRAYA dermatomyositis therapy
FDA approves LISRAYA as the first targeted oral therapy for dermatomyositis, with launch immediately.
ROIV gets FDA approval for targeted oral dermatomyositis therapy
ROIV says the FDA approved LISRAYA as the first targeted oral therapy for adult dermatomyositis.